These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6019872)

  • 21. Mycoplasma in collagen diseases and blood dyscrasia.
    Jansson E; Wager O
    Ann N Y Acad Sci; 1967 Jul; 143(1):535-43. PubMed ID: 5233786
    [No Abstract]   [Full Text] [Related]  

  • 22. Experimental Mycoplasma pneumoniae infection of young guinea pigs.
    Brunner H; James WD; Horswood RL; Chanock RM
    J Infect Dis; 1973 Mar; 127(3):315-8. PubMed ID: 4688927
    [No Abstract]   [Full Text] [Related]  

  • 23. [Modification of mycoplasma neutralization reaction].
    Prozorovskiĭ SV; Bochko GM
    Lab Delo; 1967; 3():173-6. PubMed ID: 4172602
    [No Abstract]   [Full Text] [Related]  

  • 24. [Isolation and identification of L forms and Mycoplasma from clinical material].
    Kagan GJ
    Z Gesamte Hyg; 1971 Oct; 17(10):788-98. PubMed ID: 5004404
    [No Abstract]   [Full Text] [Related]  

  • 25. Isolation of fastidious mycoplasma from human sources.
    Jansson E
    J Clin Pathol; 1971 Feb; 24(1):53-6. PubMed ID: 5573003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Destruction of virus-infected cells by immunological mechanisms.
    Porter DD
    Annu Rev Microbiol; 1971; 25():283-90. PubMed ID: 5005028
    [No Abstract]   [Full Text] [Related]  

  • 27. Factors involved in growth-inhibition of mycoplasma by immune serum.
    Riggs S; Sharp JT; Carpenter RR
    Ann N Y Acad Sci; 1967 Jul; 143(1):784-93. PubMed ID: 4964015
    [No Abstract]   [Full Text] [Related]  

  • 28. Type-C oncovirus isolate from human leukemic bone marrow: further in vitro and in vivo characterization.
    Nooter K; Overdevest J; Dubbes R; Koch G; Bentvelzen P; Zurcher C; Coolen J; Calafat J
    Int J Cancer; 1978 Jan; 21(1):27-34. PubMed ID: 203541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heat lability of rabbit anti-Mycoplasma pneumoniae serum.
    Coleman LH; Lynn RJ
    Antonie Van Leeuwenhoek; 1972; 38(2):193-200. PubMed ID: 4537444
    [No Abstract]   [Full Text] [Related]  

  • 30. The evaluation of the metabolic-inhibition technique for the study of Mycoplasma gallisepticum.
    Taylor-Robinson D; Berry DM
    J Gen Microbiol; 1969 Jan; 55(1):127-37. PubMed ID: 5775117
    [No Abstract]   [Full Text] [Related]  

  • 31. Failure to isolate a transmissible agent from the bone-marrow of patients with multiple sclerosis.
    Mitchell DN; Goswami KK; Taylor P; Salsbury AJ; Porterfield JS; Micheletti R; Lange LS; Jacobs JP; Hockley DJ; Taylor-Robinson DA
    Lancet; 1979 Aug; 2(8139):415-6. PubMed ID: 89469
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunochemical analysis of Mycoplasma pneumoniae. 2. Properties of chloroform-methanol extract from M. pneumoniae.
    Lemcke RM; Plackett P; Shaw EJ; Marmion BP
    Aust J Exp Biol Med Sci; 1968 Apr; 46(2):123-39. PubMed ID: 4297746
    [No Abstract]   [Full Text] [Related]  

  • 33. Absence of an all-or-none type of complement requirement in early neutralizing antibody against western equine encephalitis virus.
    Yoshino K; Morishima T; Aoki Y
    Jpn J Microbiol; 1971 Jan; 15(1):63-72. PubMed ID: 5313614
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative studies of hepatitis "candidate" agents and parvovirus in Detroit-6 cell cultures.
    Berquist KR; Maynard JE; Sheller M; Schable CA
    J Infect Dis; 1972 Aug; 126(2):203-6. PubMed ID: 5066210
    [No Abstract]   [Full Text] [Related]  

  • 35. [Comparative study of some biological properties of different Mycoplasma species].
    Kovalenko IaR; Siderov MA; Iablonskaia IA; Shegidevich EA
    Arch Exp Veterinarmed; 1974; 28(1):135-41. PubMed ID: 4603420
    [No Abstract]   [Full Text] [Related]  

  • 36. A division by micro-complement fixation tests of previously reported avian mycoplasma serotypes into identification groups.
    Frey ML; Hawk ST; Hale PA
    Avian Dis; 1972; 16(4):780-92. PubMed ID: 5079876
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of lysozyme and character of antibodies in experimental viral infection.
    Mĕstecký J; Medlín J
    Acta Virol; 1967 May; 11(3):206-15. PubMed ID: 4382473
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of the phagocyte in host-parasite interactions. 38. Metabolic activities of the phagocyte as related to antimicrobial action.
    Sbarra AJ; Paul BB; Jacobs AA; Strauss RR; Mitchell GW
    J Reticuloendothel Soc; 1972 Aug; 12(2):109-26. PubMed ID: 4561656
    [No Abstract]   [Full Text] [Related]  

  • 39. Complement components required for virus neutralization by early immunoglobulin antibody.
    Linscott WD; Levinson WE
    Proc Natl Acad Sci U S A; 1969 Oct; 64(2):520-7. PubMed ID: 4982356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Demonstration of complement-dependent and independent systems in immune inactivation of Mycoplasma meleagridis.
    Matsumoto M; Yamamoto R
    J Infect Dis; 1973 Mar; 127():Suppl:S43-51. PubMed ID: 4734701
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.